Nektar TherapeuticsNKTRNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank14
3Y CAGR-15.7%
5Y CAGR-18.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-15.7%/yr
vs -10.4%/yr prior
5Y CAGR
-18.3%/yr
Consistent
Acceleration
-5.3pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $186.42M | +7.8% |
| 2024 | $172.94M | -9.4% |
| 2023 | $190.90M | -38.5% |
| 2022 | $310.66M | -40.6% |
| 2021 | $523.11M | +1.9% |
| 2020 | $513.36M | -3.7% |
| 2019 | $533.28M | +10.9% |
| 2018 | $480.98M | +49.9% |
| 2017 | $320.82M | +29.3% |
| 2016 | $248.08M | - |